What is edaravone for?
Edaravone is a radical scavenger used to treat patients with acute cerebral infarction1,2. Edaravone is used also for the treatment of patients with ALS3,4.
How does edaravone work?
Free radicals such as hydroxyl radical (-OH) play a major causative role in the development of cerebral vascular disorder resulting from ischaemia. During ischaemia or ischaemic reperfusion, the production of free radicals increases which leads to cell membrane injury and ultimately to cerebral dysfunction. By eliminating free radicals, it is effective to suppress cell membrane lipid peroxidation1,2.
Where has edaravone been approved?
Edaravone was approved by the PMDA (JAP) for the treatment of acute cerebral infarction1,2.
The active ingredient edaravone is the main component of a drug produced by Mitsubishi Tanabe named Radicut in Japan and Radicava in USA. Under these names, edaravone is approved for the treatment of patients affected by ALS. The results of the clinical studies on patients affected by ALS can be found in our resources section6,7,8.
How is edaravone taken?
Complete information about edaravone dosage and administration for the treatment of cerebral infarction can be found in our resources section1,2.
- 30 mg of edaravone administered intravenously over 30 minutes twice a day in the morning and the evening.
- Administration of this product should be initiated within 24 hours after the onset of the disease, and the duration of administration should be within 14 days.
- Consider terminating administration in a shorter period depending on symptoms.
Edaravone is the active ingredient of two other drugs, Radicut and Radicava, which are indicated for the treatment of ALS. The standard dosage of Radicut and Radicava for adult patients with ALS is3,4:
- 60 mg of edaravone (2 vials/bags) administered intravenously over 60 minutes once a day.
- First cycle: daily dosing for 14 days followed by a 14-day drug-free period (28 vials/bags).
- Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods (20 vials/bags).
Edaravone is supplied in two formats:
- Single-dose infusion bags containing 30 mg / 100 mL clear, colorless, sterile solution. The infusion bags are ready for use. No dilution is required2.
- Single-dose vials containing 30 mg / 20 mL clear, colorless, sterile solution. Before the infusion, it should be diluted with an appropriate volume of physiological saline1.
Warning: Administer carefully to patients with renal dysfunction and dehydration, infectious diseases, liver dysfunction, heart disease, advanced consciousness disorder and to elderly people1,2.
Note: Please consult with your treating doctor for personalised dosing.